Open Access Open Access  Restricted Access Subscription or Fee Access

Intraperitoneal Administration of Low Dose Aluminium in The Rat: How Good is It to Produce a Model for Alzheimer Disease

H. B. Ulusoy, M. F. Sonmez, E. Kilic, K. Caliskan, B. Karaca, M. Kara, O. Ercal, Y. Gunduz, D. Karabulut, S. Bitiktas, B. Tan, S. Kavraal, A. İnal, C. Suer


Since neurotoxicity of aluminium (Al) resembles the progressive neurodegeneration observed in Alzheimer Disease (AD), Al administration in several ways has been used to produce AD model. Intraperitoneal (ip) low dose (4.2 mg/ kg) Al injection in rats for long periods is the preferred method by some researchers. In this paper, the efficiency of this method for producing an AD model was evaluated. In this study, we looked at the neuropathology of Al and the characteristic lesions of AD by histological and immunohistochemical techniques and determined oxidative stress markers in the brains of Al-treated and control rats. We also made electrophysiological recordings at the hippocampus and evaluated possible behavioural changes by Morris water maze test. However, no pathologic changes occurred in the animals except for an impairment in long-term potentiation (LTP) in the hippocampus (e.g. the LTPs of population spike (PS) amplitude at 15 min post-tetanus were measured as 217±27% in Al-treated rats and as 240±42% in sham-treated rats, of baseline PS amplitude). According to the findings of the present study, low dose of ip Al in rats is not sufficient to produce a good AD model. Higher doses (≥10 mg/kg) should be used.


Alzheimer Disease, Aluminium, Long-term Potentiation, Immunohistochemistry, Oxidative Stress

Full Text:



Abdel-Aal RA, Assi AA, Kostandy BB. Memantine prevents aluminum-induced cognitive deficit in rats. Behavioural brain research, 2011; 225: 31-8.

Abubakar M, Taylor A, Ferns G. The effects of aluminium and selenium supplementation on brain and liver antioxidant status in the rat. African Journal of Biotechnology, 2004; 3: 88-93.

Akiyama H, Hosokawa M, Kametani F, Kondo H, Chiba M, Fukushima M, Tabira T. Long-term oral intake of aluminium or zinc does not accelerate Alzheimer pathology in AbetaPP and AbetaPP/tau transgenic mice. Neuropathology : official journal of the Japanese Society of Neuropathology, 2012; 32: 390-7.

Aly HF, Metwally FM, Ahmed HH. Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer's disease. Acta Biochim Pol, 2011; 58: 513-20.

Bharathi VP, Govindaraju M, Palanisamy AP, Sambamurti K, Rao KS. Molecular toxicity of aluminium in relation to neurodegeneration. The Indian journal of medical research, 2008; 128: 545-56.

Cabus N, Oguz E, Tufan A, Adiguzel E. A histological study of toxic effects of aluminium sulfate on rat hippocampus. Biotechnic & histochemistry : official publication of the Biological Stain Commission, 2014: 1-8.

Chakrabarty M, Bhat P, Kumari S, D'Souza A, Bairy KL, Chaturvedi A, Natarajan A, Rao MK, Kamath S. Cortico-hippocampal salvage in chronic aluminium induced neurodegeneration by Celastrus paniculatus seed oil: Neurobehavioural, biochemical, histological study. Journal of pharmacology & pharmacotherapeutics, 2012; 3: 161-71.

Chen J, Wang M, Ruan D, She J. Early chronic aluminium exposure impairs long-term potentiation and depression to the rat dentate gyrus in vivo. Neuroscience, 2002; 112: 879-87.

Cunat L, Lanhers MC, Joyeux M, Burnel D. Bioavailability and intestinal absorption of aluminum in rats: effects of aluminum compounds and some dietary constituents. Biological trace element research, 2000; 76: 31-55.

D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain research. Brain research reviews, 2001; 36: 60-90.

Dickson DW. The pathogenesis of senile plaques. Journal of neuropathology and experimental neurology, 1997; 56: 321-39.

Ellis HA, McCarthy JH, Herrington J. Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation. Journal of clinical pathology, 1979; 32: 832-44.

Esparza JL, Gomez M, Romeu M, Mulero M, Sanchez DJ, Mallol J, Domingo JL. Aluminum-induced pro-oxidant effects in rats: protective role of exogenous melatonin. Journal of pineal research, 2003; 35: 32-9.

Exley C, Esiri MM. Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UK. Journal of neurology, neurosurgery, and psychiatry, 2006; 77: 877-9.

Exley C, Vickers T. Elevated brain aluminium and early onset Alzheimer's disease in an individual occupationally exposed to aluminium: a case report. Journal of medical case reports, 2014; 8: 41.

Flaten TP. Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. Brain research bulletin, 2001; 55: 187-96.

Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Annals of the New York Academy of Sciences, 1996; 777: 121-31.

Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals, 2014; 7: 990-8.

House E, Esiri M, Forster G, Ince PG, Exley C. Aluminium, iron and copper in human brain tissues donated to the Medical Research Council's Cognitive Function and Ageing Study. Metallomics : integrated biometal science, 2012; 4: 56-65.

Jain SK. Evidence for membrane lipid peroxidation during the in vivo aging of human erythrocytes. Biochimica et biophysica acta, 1988; 937: 205-10.

Klatzo I, Wisniewski H, Streicher E. Experimental Production of Neurofibrillary Degeneration. I. Light Microscopic Observations. Journal of neuropathology and experimental neurology, 1965; 24: 187-99.

Mohamd EM, Ahmed HH, Estefan SF, Farrag AE, Salah RS. Windows into estradiol effects in Alzheimer's disease therapy. European review for medical and pharmacological sciences, 2011; 15: 1131-40.

Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. Journal of neuroscience methods, 1984; 11: 47-60.

Neill D, Leake A, Hughes D, Keith AB, Taylor GA, Allsop D, Rima BK, Morris C, Candy JM, Edwardson JA. Effect of aluminium on expression and processing of amyloid precursor protein. Journal of neuroscience research, 1996; 46: 395-403.

Nivsarkar M, Banerjee A. Establishing the probable mechanism of L-DOPA in Alzheimer's disease management. Acta poloniae pharmaceutica, 2009; 66: 483-6.

Nivsarkar M, Banerjee A, Shah D, Trivedi J, Patel M, Cherian B, Padh H. Reduction in aluminum induced oxidative stress by Meloxicam in rat brain. Iranian Biomedical Journal, 2006; 10: 151-5.

Platt B, Carpenter DO, Busselberg D, Reymann KG, Riedel G. Aluminum impairs hippocampal long-term potentiation in rats in vitro and in vivo. Experimental neurology, 1995; 134: 73-86.

Pohanka M. Alzheimer s disease and oxidative stress: a review. Current medicinal chemistry, 2013; 21: 356-64.

Prajda N, Weber G. Malignant transformation-linked imbalance: decreased xanthine oxidase activity in hepatomas. FEBS letters, 1975; 59: 245-9.

Sanchez-Iglesias S, Mendez-Alvarez E, Iglesias-Gonzalez J, Munoz-Patino A, Sanchez-Sellero I, Labandeira-Garcia JL, Soto-Otero R. Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: potential effects in a 6-OHDA-induced model of Parkinson's disease. Journal of neurochemistry, 2009; 109: 879-88.

Sanchez-Iglesias S, Soto-Otero R, Iglesias-Gonzalez J, Barciela-Alonso MC, Bermejo-Barrera P, Mendez-Alvarez E. Analysis of brain regional distribution of aluminium in rats via oral and intraperitoneal administration. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements, 2007; 21 Suppl 1: 31-4.

Singh S, Singh R, Kushwah AS, Gupta G. Neuroprotective role of antioxidant and pyranocarboxylic acid derivative against AlCl3 induced Alzheimer’s disease in rats. Journal of Coastal Life Medicine, 2014; 2: 547-54.

Slanina P, Frech W, Bernhardson A, Cedergren A, Mattsson P. Influence of dietary factors on aluminium absorption and retention in the brain and bone of rats. Acta pharmacologica et toxicologica, 1985; 56: 331-6.

Sonmez MF, Narin F, Balcioglu E. Melatonin and vitamin C attenuates alcohol-induced oxidative stress in aorta. Basic & clinical pharmacology & toxicology, 2009; 105: 410-5.

Sonmez MF, Ozan E. Determination of ghrelin immunoreactivity in the rat stomach after fasting and refeeding. Acta histochemica, 2007; 109: 193-9.

Swomley AM, Forster S, Keeney JT, Triplett J, Zhang Z, Sultana R, Butterfield DA. Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochimica et biophysica acta, 2014; 1842: 1248-57.

Turgut S, Bor-Kucukatay M, Emmungil G, Atsak P, Turgut G. The effects of low dose aluminum on hemorheological and hematological parameters in rats. Arch Toxicol, 2007; 81: 11-7.

Walton JR. Aluminum in hippocampal neurons from humans with Alzheimer's disease. Neurotoxicology, 2006; 27: 385-94.

Wang M, Chen JT, Ruan DY, Xu YZ. Vasopressin reverses aluminum-induced impairment of synaptic plasticity in the rat dentate gyrus in vivo. Brain research, 2001; 899: 193-200.

Ward NI, Abou-Shakra FR, Durrant SF. Trace elemental content of biological materials. A comparison of NAA and ICP-MS analysis. Biological trace element research, 1990; 26-27: 177-87.

Xu N, Majidi V, Markesbery WR, Ehmann WD. Brain aluminum in Alzheimer's disease using an improved GFAAS method. Neurotoxicology, 1992; 13: 735-43.

Yuan CY, Lee YJ, Hsu GS. Aluminum overload increases oxidative stress in four functional brain areas of neonatal rats. J Biomed Sci, 2012; 19: 51.

Zhang L, Jin C, Liu Q, Lu X, Wu S, Yang J, Du Y, Zheng L, Cai Y. Effects of subchronic aluminum exposure on spatial memory, ultrastructure and L-LTP of hippocampus in rats. The Journal of toxicological sciences, 2013; 38: 255-68.

Shuchang H, Qiao N, Piye N, Mingwei H, Xiaoshu S, Feng S, Sheng W, Opler M.Protective effects of gastrodia elata on aluminium-chloride-induced learning impairments and alterations of amino acid neurotransmitter release in adult rats. Restor Neurol Neurosci. 2008;26(6):467-73.



  • There are currently no refbacks.